Quin is an MD/PhD with few extra degrees in genomics, mathematics, and statistical/machine learning. He uses deep genomic phenotyping technologies to develop RNA therapies for chronic liver disease. He started his first liver genomics company 17 years ago, and was most recently Head of Cellular and Systems Genomics for Novo Nordisk before co-founding Ochre Bio. Ochre Bio is a series A company, with labs in Oxford, Taipei, and New York where they regenerate human livers not good enough for transplantation. Think farms of livers on machines being refurbished by direct RNA reprogramming, so that fewer patients die waiting for a new liver.